Leerink Partnrs Has Negative Outlook of UTHR FY2024 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Equities researchers at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for United Therapeutics in a report issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of $25.09 for the year, down from their previous forecast of $25.94. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q1 2025 earnings at $6.95 EPS, Q2 2025 earnings at $7.31 EPS, Q3 2025 earnings at $7.81 EPS, FY2025 earnings at $29.77 EPS, FY2026 earnings at $31.02 EPS, FY2027 earnings at $30.53 EPS and FY2028 earnings at $32.83 EPS.

Several other brokerages have also recently issued reports on UTHR. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. UBS Group upped their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. TD Cowen raised their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Stock Up 2.2 %

Shares of NASDAQ UTHR opened at $353.31 on Wednesday. The firm’s 50-day moving average price is $362.06 and its 200-day moving average price is $358.24. United Therapeutics has a 52-week low of $210.64 and a 52-week high of $417.82. The company has a market cap of $15.78 billion, a PE ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57.

Insiders Place Their Bets

In related news, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 121,864 shares of company stock worth $44,516,965. Corporate insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Florida Financial Advisors LLC raised its stake in United Therapeutics by 6.2% during the fourth quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company’s stock valued at $290,000 after purchasing an additional 48 shares in the last quarter. Prudential Financial Inc. raised its position in shares of United Therapeutics by 22.2% during the 4th quarter. Prudential Financial Inc. now owns 66,541 shares of the biotechnology company’s stock valued at $23,478,000 after buying an additional 12,104 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company’s stock valued at $1,567,253,000 after acquiring an additional 32,213 shares during the last quarter. LPL Financial LLC lifted its holdings in shares of United Therapeutics by 122.8% in the 4th quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company’s stock valued at $5,024,000 after acquiring an additional 7,847 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in United Therapeutics in the fourth quarter worth about $429,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.